Article
Oncology
Seohyuk Lee, Chao Ma, Qian Shi, Pankaj Kumar, Felix Couture, Philip Kuebler, Smitha Krishnamurthi, DeQuincy Lewis, Benjamin Tan, Richard M. Goldberg, Alan Venook, Charles Blanke, Eileen M. O'Reilly, Anthony F. Shields, Jeffrey A. Meyerhardt
Summary: This study aimed to evaluate the independent and interactive associations of planned treatment duration, celecoxib use, physical activity, BMI, diabetes, and vitamin B6 with Oxaliplatin-induced peripheral neuropathy (OIPN). The results showed that longer treatment cycles, lower physical activity, higher BMI, and diabetes were significantly associated with increased OIPN severity.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Shoshana M. Rosenberg, Yue Zheng, Shari Gelber, Kathryn J. Ruddy, Philip Poorvu, Tal Sella, Rulla M. Tamimi, Johanna Wassermann, Lidia Schapira, Virginia F. Borges, Steven Come, Jeffrey Peppercorn, Karen R. Sepucha, Ann H. Partridge
Summary: This study aims to understand the non-initiation and non-persistence of oral adjuvant endocrine therapy (ET) in young women with breast cancer and propose corresponding interventions. The results showed that black women were more likely to have non-initiation, while women with a college degree were more likely to initiate treatment. Non-persistence was associated with younger age, being married/partnered, and having more weight problems. After adjusting for age and clinical characteristics, non-persistence was associated with lower odds of recurrence.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
I van den Berg, S. van de Weerd, D. van Klaveren, R. R. J. Coebergh van den Braak, J. H. J. M. van Krieken, M. Koopman, J. M. L. Roodhart, J. P. Medema, J. N. M. IJzermans
Summary: This study revealed significant variation in guideline adherence to adjuvant chemotherapy among stage III colon cancer patients, with poor documentation on reasons for non-adherence. Patients who received adjuvant chemotherapy had longer recurrence free survival (RFS), and high T- and N-stage were associated with poorer RFS. Risk groups were identified with distinct prognosis and treatment effect, emphasizing the importance of adherence to guidelines for improved patient outcomes.
Article
Oncology
Justin C. C. Brown, Chao Ma, Qian Shi, Charles S. S. Fuchs, Jeffrey Meyer, Donna Niedzwiecki, Tyler Zemla, Felix Couture, Philip Kuebler, Pankaj Kumar, DeQuincy Lewis, Benjamin Tan, Smitha Krishnamurthi, Eileen M. M. O'Reilly, Anthony F. F. Shields, Jeffrey A. A. Meyerhardt
Summary: The purpose of this study was to determine the specific types, durations, and intensities of recreational physical activity that are associated with the greatest improvements in disease-free survival (DFS) for patients with colon cancer. The study found that engaging in larger volumes of recreational physical activity, longer durations of light-to-moderate-intensity aerobic exercise, or any vigorous-intensity aerobic exercise were significantly associated with improved DFS.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Chanhyun Park, Ji-Haeng Heo, Sanica Mehta, Sola Han, Jennifer C. Spencer
Summary: This study aimed to estimate the impact of individual adjuvant endocrine therapy (AET) types on treatment efficacy and overall survival in breast cancer patients. The study found that the tamoxifen group had a faster decrease in adherence compared to anastrozole, letrozole, and exemestane, and higher adherence was associated with a lower risk of mortality.
CLINICAL DRUG INVESTIGATION
(2023)
Article
Oncology
Dario Trapani
Summary: The Oncology Grand Rounds series aims to provide clinical context for original reports published in the Journal. It includes case presentations, discussions on diagnostic and management challenges, reviews of relevant literature, and summaries of suggested management approaches. The series helps readers understand how to apply key study results to their own clinical practice.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Julia Foldi, Anastasia Tsagianni, Max Salganik, Catherine A. Schnabel, Adam Brufsky, G. J. van Londen, Lajos Pusztai, Tara Sanft
Summary: Extending adjuvant endocrine therapy beyond the standard 5 years can protect against late breast cancer recurrences. This study evaluated persistence to extended therapy in women who had Breast Cancer Index testing, and found high rates of persistence in patients with predicted high likelihood of benefit.
Article
Oncology
Ann S. LaCasce, Travis Dockter, Amy S. Ruppert, Lale Kostakoglu, Heiko Schoder, Eric Hsi, Jeffrey Bogart, Bruce Cheson, Nina Wagner-Johnston, Jeremy Abramson, Kristie Blum, John P. Leonard, Nancy L. Bartlett
Summary: Patients with bulky stage I/II classic Hodgkin lymphoma (cHL) were treated with PET-adapted therapy, which omitted radiation in PET-negative patients and intensified treatment in PET-positive patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Yu-Hsuan Shih, Hsin-Chen Lin, Po-Wei Liao, Cheng-Wei Chou, Cheng-Hsien Lin, Chiann-Yi Hsu, Chieh-Lin Jerry Teng, Feng-Hsu Wu, Shao-Ciao Luo, Shao-Hsuan Kao
Summary: This study aimed to investigate the clinical impact of adjuvant chemotherapy in older patients with stage II/III gastric cancer. It found that older patients who received adjuvant chemotherapy had improved disease-free survival and overall survival compared to those who did not receive this treatment. Further prospective studies are needed to confirm these findings.
Article
Oncology
Jeffrey Bogart, Xiaofei Wang, Gregory Masters, Junheng Gao, Ritsuko Komaki, Laurie E. Gaspar, John Heymach, James Bonner, Charles Kuzma, Saiama Waqar, William Petty, Thomas E. Stinchcombe, Jeffrey D. Bradley, Everett Vokes
Summary: A randomized trial found that 45-Gy twice-daily radiotherapy is still the standard treatment for limited-stage small-cell lung cancer, despite the fact that most patients receive higher-dose once-daily regimens in clinical practice. This study provides the most robust information available to guide the choice of thoracic radiotherapy regimen for patients with limited-stage small-cell lung cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Sheng-Kai Liang, Chang-Wei Wu, Ching- Chang, Li-Ta Keng, Meng-Rui Lee, Jann-Yuan Wang, Jen-Chung Ko, Wei-Yu Liao, Kuan-Yu Chen, Chao-Chi Ho, Jin-Yuan Shih, Chong-Jen Yu
Summary: This study compared the effectiveness of adjuvant oral UFT and intravenous chemotherapy in early-stage NSCLC patients after surgery and found that both treatments had comparable clinical outcomes.
Article
Oncology
Oluchi Oke, Jiangong Niu, Mariana Chavez-MacGregor, Hui Zhao, Sharon H. Giordano
Summary: The study found a high rate of tamoxifen discontinuation among male breast cancer patients, with even among those continuing treatment a substantial number of non-adherent patients.
Review
Oncology
M. Chadha, J. White, S. M. Swain, E. Rakovitch, R. Jagsi, T. Whelan, J. A. Sparano
Summary: Older women are underrepresented in breast cancer clinical trials, and treatment guidelines are primarily based on studies in younger women. Omission of breast radiation therapy is associated with increased local relapse, but the risk of distant relapse in women aged 70 and above is very low. The incremental benefit of endocrine therapy in decreasing distant relapse rate and improving disease-free survival in older patients with low-risk breast cancer is unclear. Integration of molecular genomic assays in diagnosis and treatment may optimize risk-tailored adjuvant therapies, allowing for treatment de-escalation in older women with early-stage breast cancer. The lack of risk-specific adjuvant therapy guidelines highlights the need for prospective trials to inform optimal treatment selection, including the possibility of omitting adjuvant endocrine therapy in older women with low-risk breast cancer.
Article
Oncology
Emily Jones, Zhigang Duan, Thinh T. Nguyen, Sharon H. Giordano, Hui Zhao
Summary: This study evaluated the patterns of different drug regimens used in adjuvant chemotherapy for high-risk stage II or III colon cancer patients, as well as their association with survival and rates of emergency room visits or hospitalizations. The study found that FLOX/OX regimen was associated with improved survival, while capecitabine regimen had the lowest rates of emergency room visits or hospitalizations.
Article
Medicine, General & Internal
Jeanne Tie, Joshua D. Cohen, Kamel Lahouel, Serigne N. Lo, Yuxuan Wang, Suzanne Kosmider, Rachel Wong, Jeremy Shapiro, Margaret Lee, Sam Harris, Adnan Khattak, Matthew Burge, Marion Harris, James Lynam, Louise Nott, Fiona Day, Theresa Hayes, Sue-Anne McLachlan, Belinda Lee, Janine Ptak, Natalie Silliman, Lisa Dobbyn, Maria Popoli, Ralph Hruban, Anne Marie Lennon, Nicholas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Cristian Tomasetti, Peter Gibbs
Summary: This study found that using ctDNA results to guide treatment decisions for stage II colon cancer reduced the use of adjuvant chemotherapy without compromising recurrence-free survival.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Julienne E. Bower, Ann H. Partridge, Antonio C. Wolff, Steve W. Cole, Michael R. Irwin, Elissa D. Thorner, Hadine Joffe, Laura Petersen, Catherine M. Crespi, Patricia A. Ganz
Summary: This study examined the effects of interventions on younger breast cancer survivors and found that mindful awareness practices (MAPs) had beneficial effects on psychological and immune outcomes, indicating its potential for enhancing biobehavioral health.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Article
Oncology
Adith Abraham, Carlos H. Barcenas, Richard J. Bleicher, Adam L. Cohen, Sara H. Javid, Ellis G. Levine, Nancy U. Lin, Beverly Moy, Joyce C. Niland, Antonio C. Wolff, Michael J. Hassett, Sarah Asad, Daniel G. Stover
Summary: We developed a risk prediction model for late relapse of triple negative breast cancer (lrTNBC) using clinicopathologic and sociodemographic features. Our study found that tumor stage at diagnosis and BMI were significantly associated with lrTNBC. This risk prediction model may help identify patients at risk of developing lrTNBC and should be further investigated.
Article
Oncology
Kala Visvanathan, Leslie Cope, Mary Jo Fackler, Michael Considine, Lori Sokoll, Lisa A. Carey, Andres Forero-Torres, James N. Ingle, Nancy U. Lin, Rita Nanda, Anna Maria Storniolo, Suzana Tulac, Neesha Venkatesan, Natalie C. Wu, Sudhakar Marla, Scott Campbell, Michael Bates, Christopher B. Umbricht, Antonio C. Wolff, Saraswati Sukumar
Summary: This study evaluated the clinical utility of a novel liquid biopsy-breast cancer methylation (LBx-BCM) prototype assay for early assessment of disease progression in women with metastatic breast cancer (MBC). The results showed that high levels of cumulative methylation (CM) were associated with shorter median progression-free survival (PFS) and overall survival (OS) at week 4. The CM levels at week 4 could be used to predict disease progression as early as 3 months after initiating a new treatment.
CLINICAL CANCER RESEARCH
(2023)
Editorial Material
Oncology
Cesar A. Santa-Maria, Antonio C. Wolff
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Zhengyi Deng, Miranda R. Jones, Mei-Cheng Wang, Antonio C. Wolff, Kala Visvanathan
Summary: Higher cancer mortality was observed among Non-Hispanic Black and Hispanic survivors, while higher cardiovascular mortality was observed among Non-Hispanic Black survivors among women who survive a first breast cancer to develop a second primary cancer.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Article
Oncology
Jennifer Y. Sheng, Claire F. Snyder, Katherine C. Smith, Jennifer DeSanto, Nancy Mayonado, Susan Rall, Sharon White, Amanda L. Blackford, Fabian M. Johnston, Robert L. Joyner, Joan Mischtschuk, Kimberly S. Peairs, Elissa Thorner, Phuoc T. Tran, Antonio C. Wolff, Youngjee Choi
Summary: Survivorship care plans (SCPs) are important for communicating cancer-related information. This study found that some tests conducted after SCP receipt were not consistent with guidelines, indicating overuse. This analysis identifies areas for improvement in guideline-concordant care.
Article
Oncology
Gabrielle B. Rocque, Courtney Andrews, Valerie M. Lawhon, Rachel Frazier, Stacey A. Ingram, Mary Lou Smith, Lynne I. Wagner, Lisa Zubkoff, Nadine Tung, Lauren P. Wallner, Antonio C. Wolff
Summary: As outcomes improve in early-stage breast cancer, clinical trials are shifting towards optimization trials, which aim to use less toxic therapy while maintaining survival outcomes. However, little is known about physician perspectives on the barriers and facilitators to enrollment in these trials and the generalizability of the results.
JCO ONCOLOGY PRACTICE
(2023)
Article
Oncology
Susana L. Garcia-Recio, Toshinori J. Hinoue, Gregory L. C. Wheeler, Benjamin J. Kelly, Ana C. A. Garrido-Castro, Tomas Pascual, Aguirre A. M. De Cubas, Youli B. Xia, Brooke M. Felsheim, Marni B. McClure, Andrei A. Rajkovic, Ezgi Karaesmen, Markia A. Smith, Cheng E. Fan, Paula I. Gonzalez J. Ericsson, Melinda E. Sanders, Chad J. Creighton, Jay T. Bowen, Kristen Leraas, Robyn T. Burns, Sara Coppens, Amy L. Wheless, Salma S. Rezk, Amy L. K. Garrett, Joel S. Parker, Kelly K. H. Foy, Hui Shen, Ben H. Park, Ian Krop, Carey F. Anders, Julie Gastier-Foster, Mothaffar F. U. Rimawi, Rita Nanda, Nancy U. Lin, Claudine Isaacs, P. Kelly J. Marcom, Anna Maria Storniolo, Fergus J. Couch, Uma Chandran, Michael Davis, Jonathan C. Silverstein, Alexander G. Ropelewski, Minetta C. Liu, Susan G. L. Hilsenbeck, Larry Norton, Andrea L. C. Richardson, W. Fraser E. Symmans, Antonio C. A. Wolff, Nancy E. V. Davidson, Lisa A. M. Carey, Adrian V. A. Lee, Justin M. W. Balko, Katherine A. R. Hoadley, Peter W. A. Laird, Elaine R. A. Mardis, Tari A. A. King, Charles M. AURORA US Network, Charles M. Perou
Summary: The AURORA US Metastasis Project aimed to identify molecular features associated with metastasis in breast cancer. By analyzing the samples from 55 females with metastatic breast cancer, changes in gene expression subtypes and DNA clonality shifts were observed. Downregulation of estrogen receptor (ER)-mediated cell-cell adhesion genes through DNA methylation mechanisms was observed in metastases. Differences in the tumor microenvironment and immune cell infiltrates were also found in different breast cancer subtypes, providing implications for targeted therapies.
Review
Oncology
Laura Pala, Tommaso De Pas, Eleonora Pagan, Isabella Sala, Chiara Catania, Emma Zattarin, Paolo Arnone, Massimo M. Grassi, Marco Colleoni, Antonio C. Wolff, Javier Cortes, Martine Piccart, Richard D. Gelber, Giuseppe Viale, Vincenzo Bagnardi, Fabio Conforti
Summary: This study conducted a systematic review and meta-analysis of randomized clinical trials to compare the efficacy of limited-extended adjuvant endocrine treatment (ET) and full-extended ET in patients with early-stage breast cancer. The results showed that full-extended ET significantly improved disease-free survival (DFS) in patients with nodal-positive disease, while no significant improvement was observed in other subgroups.
Editorial Material
Oncology
Clifford A. Hudis
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Antonio C. Wolff, Mark R. Somerfield, Mitchell Dowsett, M. Elizabeth H. Hammond, Daniel F. Hayes, Lisa M. McShane, Thomas J. Saphner, Patricia A. Spears, Kimberly H. Allison
Summary: This article is an update on the recommendations for HER2 testing in breast cancer, affirming the 2018 ASCO-CAP recommendations. The article emphasizes a new indication for trastuzumab deruxtecan when HER2 is not overexpressed or amplified, and provides best practice recommendations to distinguish IHC 0 and 1+.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Beverly Moy, Antonio C. Wolff, R. Bryan Rumble, Kimberly H. Allison, Lisa A. Carey
JCO ONCOLOGY PRACTICE
(2023)
Editorial Material
Oncology
Antonio C. Wolff
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Zhengyi Deng, Miranda R. Jones, Antonio C. Wolff, Kala Visvanathan
Summary: The UK National Health Service's Predict tool performs well in predicting breast cancer-specific mortality for first breast cancer, but underestimates it for second breast cancer, especially for estrogen receptor-positive breast cancer patients.
JNCI CANCER SPECTRUM
(2023)
Article
Oncology
Sara M. Tolaney, Paolo Tarantino, Noah Graham, Nabihah Tayob, Laia Pare, Guillermo Villacampa, Chau Dang, Denise A. Yardley, Beverly Moy, P. Kelly Marcom, Kathy S. Albain, Hope S. Rugo, Matthew J. Ellis, Iuliana Shapira, Antonio C. Wolff, Lisa A. Carey, Romualdo Barroso-Sousa, Patricia Villagrasa, Michelle DeMeo, Molly DiLullo, Jorge Gomez Tejeda Zanudo, Jakob Weiss, Nikhil Wagle, Ann H. Partridge, Adrienne G. Waks, Clifford A. Hudis, Ian E. Krop, Harold J. Burstein, Aleix Prat, Eric P. Winer
Summary: This study reports the long-term outcomes of patients with small, node-negative, HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab, and establishes potential biomarkers to predict prognosis. The results indicate that adjuvant paclitaxel and trastuzumab is a reasonable treatment standard for this population, and the HER2DX genomic tool might help refine the prognosis.